Amgen's weight-loss drug fails to impress in study; shares plunge
Amgen's experimental drug MariTide helped overweight or obese patients shed up to 20% of their body weight in a mid-stage ...
Amgen’s stock slides 7.8% after weight-loss drug data lags analyst expectations
Amgen Inc.’s stock was down 7% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed ...
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...
Amgen drug leads to up to 20% weight loss in trial
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...
New Drug Causes 20 Percent Weigh Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY
Amgen (NASDAQ:AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide ...
Amgen shows 20% weight loss in once-monthly injectable MariTide
Amgen's latest once-monthly weight loss drug data looks "OK," analysts say, as its path to approval still remains murky.
MM&M20h
Amgen’s MariTide achieves 20% weight loss, but Wall Street remains unimpressed
Amgen released the long-awaited results from its study of weight loss injection MariTide and the results — while promising — ...
BioSpace4h
‘Bulls Disappointed’ as Amgen’s MariTide Demonstrates 20% Weight Loss
Amgen’s MariTide results are at the lower end of investors’ expectation of 20% to 25% weight loss. The much-anticipated ...
Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed
Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...
Amgen weight loss data ‘underwhelms,’ says Deutsche Bank
MariTide’s Phase 2 press release “underwhelms” with 20% weight loss from Cohort A and 17% weight loss from Cohort B at 52-weeks, with it being unclear if these are placebo adjusted. MariTide’s weight ...